Trials / Completed
CompletedNCT02770248
24-hr Intraocular Pressure Control With SIMBRINZA ®
24-hr Intraocular Pressure Control With Brinzolamide 1% / Brimonidine 0.2% Ophthalmic Suspension vs Vehicle
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 162 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate differences between treatments in mean change from baseline in 24-hr intraocular pressure (IOP) at Week 4.
Detailed description
Subjects will undergo washout of pre-study IOP-lowering medications for the appropriate duration, then undergo 2 eligibility visits. Eligible subjects will be randomized 1:1, to receive masked SIMBRINZA ® or Vehicle for 4 weeks. Two 24-hour visits will be conducted (Day 0 and Week 4) during which intraocular pressure will be collected every 2 hours. The expected duration of subject participation in the study is 10 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension | |
| DRUG | Vehicle | Inactive ingredients used as a placebo for masking purposes |
Timeline
- Start date
- 2016-05-23
- Primary completion
- 2017-01-14
- Completion
- 2017-01-14
- First posted
- 2016-05-12
- Last updated
- 2018-07-02
- Results posted
- 2018-01-04
Source: ClinicalTrials.gov record NCT02770248. Inclusion in this directory is not an endorsement.